mhurhangee/ep-ind-claims huggingface dataset:
A composition for use in treating hidradenitis suppurativa in a subject having lesions associated with hidradenitis suppurativa, the composition comprising [ -2,2-difluorocyclo-propyl][(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]oct-8-yl]methanone; or, a pharmaceutically acceptable salt thereof.
A method for automatically computing a dimension of a moving platform, said dimension being a length dimension or a width dimension, including a step for sending, by a radar system, electromagnetic radio waves toward said platform along a predetermined transmission axis and acquiring at least one digital power profile signal representative of a received reflected signal power as a function of a radial distance along said transmission axis relative to a reference point of said radar system, comprising the following steps: - applying a filtering operator on the acquired digital power profile signal (S i) making it possible to obtain a filtered digital signal, - determining, by computation, a first radial distance (dr 1) corresponding to a first variation peak of the filtered digital signal and a second radial distance (dr 2) corresponding to a second variation peak of the filtered digital signal, - computing a radial dimension of the platform as a function of said first and second radial distances, characterized in that the step for determining, by computation, a first radial distance corresponding to a first variation peak of the filtered digital signal and a second radial distance corresponding to a second variation peak of the filtered digital signal comprises a computation, done by applying a sliding window, of a partial discrete integral value of the filtered digital signal comprised in said sliding window and a comparison of the partial integral value to a predetermined variation threshold. - applying a filtering operator on the acquired digital power profile signal (S i) making it possible to obtain a filtered digital signal, - determining, by computation, a first radial distance (dr 1) corresponding to a first variation peak of the filtered digital signal and a second radial distance (dr 2) corresponding to a second variation peak of the filtered digital signal, - computing a radial dimension of the platform as a function of said first and second radial distances,
A thermoplastic blend comprising a. a polycarbonate; b. an inorganic filler; c. an impact modifier; and d. a heat stabilizer; and wherein a molded specimen of the thermoplastic blend exhibits a bonding strength of greater than 25 MPa as measured according to ISO 19095; wherein a 3.2 mm molded specimen of the thermoplastic blend has a notched Izod impact strength of greater than 150 J/m as measured according to ASTM D256 at 23°C; and wherein the thermoplastic blend has a melt volume flow rate of greater than 18 cubic centimeters per 10 minutes as measured according to ASTM D256 at 280°C under a 5 kilogram load. a. a polycarbonate; b. an inorganic filler; c. an impact modifier; and d. a heat stabilizer; and
An apparatus, comprising: a tissue-repair implant configured to reside chronically in a heart of a patient; a tissue anchor comprising: a distal tissue coupling element configured to couple the tissue anchor to tissue of the heart of the patient; and a proximal implant-receiving element (47a; 47b) configured to receive at least a portion of the tissue-repair implant and facilitate coupling of the tissue-repair implant to the tissue anchor, and a proximal implant-restraining element (53a; 53b) coupled to a proximal portion of the implant-receiving element (47a; 47b), the proximal implant-restraining element (53a; 53b) being configured to restrain the implant from separating from the implant-receiving element (47a; 47b). a tissue-repair implant configured to reside chronically in a heart of a patient; a tissue anchor comprising: a distal tissue coupling element configured to couple the tissue anchor to tissue of the heart of the patient; and a proximal implant-receiving element (47a; 47b) configured to receive at least a portion of the tissue-repair implant and facilitate coupling of the tissue-repair implant to the tissue anchor, and a proximal implant-restraining element (53a; 53b) coupled to a proximal portion of the implant-receiving element (47a; 47b), the proximal implant-restraining element (53a; 53b) being configured to restrain the implant from separating from the implant-receiving element (47a; 47b). a distal tissue coupling element configured to couple the tissue anchor to tissue of the heart of the patient; and a proximal implant-receiving element (47a; 47b) configured to receive at least a portion of the tissue-repair implant and facilitate coupling of the tissue-repair implant to the tissue anchor, and a proximal implant-restraining element (53a; 53b) coupled to a proximal portion of the implant-receiving element (47a; 47b), the proximal implant-restraining element (53a; 53b) being configured to restrain the implant from separating from the implant-receiving element (47a; 47b).
A multilayer structure comprising a barrier layer and an elastomer layer, wherein a proportion of a thickness of the elastomer layer in the multilayer structure is 60% or more and wherein the barrier layers and the elastomer layers are laminated to form seven or more layers in total.
An apparatus for radially distending a semiconductor structure having a front surface, a back surface and a circumferential edge, the apparatus comprising: a structure holder comprising a top plate and a back plate for contacting the semiconductor structure adjacent a circumferential edge of the semiconductor structure, the top plate adapted to contact the front surface of the semiconductor structure and the back plate adapted to contact the back surface of the semiconductor structure, the top plate and back plate being further adapted to form a peripheral chamber between the top plate, back plate and circumferential edge of the semiconductor structure, characterized in that the semiconductor structure comprises a dislocation source layer in a substrate and a heteroepitaxial layer and further in that the apparatus for radially distending the semiconductor structure causes generation of dislocations and gliding of the dislocations toward the heteroepitaxial layer.
A vehicle high-beam lamp control apparatus comprising: a passing switch configured to be turned off after having been turned on by means of a physical force from a user; a high-beam switch configured to turn on and off a high-beam lamp; and a control unit configured to switch on and off the high-beam lamp in accordance with an on/off state of the passing switch and the high-beam switch, characterised in that the control unit is configured to switch off the high-beam lamp if, after the passing switch has been turned on, the passing switch is not turned off such that a first set time is exceeded, and to switch off the high-beam lamp if the passing switch is turned on when the high-beam switch is in the turned on state. a passing switch configured to be turned off after having been turned on by means of a physical force from a user; a high-beam switch configured to turn on and off a high-beam lamp; and a control unit configured to switch on and off the high-beam lamp in accordance with an on/off state of the passing switch and the high-beam switch, characterised in that the control unit is configured to switch off the high-beam lamp if, after the passing switch has been turned on, the passing switch is not turned off such that a first set time is exceeded, and to switch off the high-beam lamp if the passing switch is turned on when the high-beam switch is in the turned on state.
A method for producing a racemate of a compound represented by Formula, comprising bringing a transition metal catalyst into contact with an optically active form of the compound represented by Formula: in Formula, a ring X 1 represents an aromatic ring; R 1 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, or a C 1-6 halo-alkyl group; R 2 is a group different from R 1 and represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, or a C 1-6 halo-alkyl group, or R 2 and the ring X 1 are bonded to each other to form a ring; a hydrogen atom(s) of the ring X 1 is optionally replaced with a C 1-6 alkyl group, a C 1-6 halo-alkyl group, a cyano group, a nitro group, a C 1-6 alkoxy group, or a halogen atom; and * represents an asymmetric carbon atom. a ring X 1 represents an aromatic ring; R 1 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, or a C 1-6 halo-alkyl group; R 2 is a group different from R 1 and represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, or a C 1-6 halo-alkyl group, or R 2 and the ring X 1 are bonded to each other to form a ring; a hydrogen atom(s) of the ring X 1 is optionally replaced with a C 1-6 alkyl group, a C 1-6 halo-alkyl group, a cyano group, a nitro group, a C 1-6 alkoxy group, or a halogen atom; and * represents an asymmetric carbon atom.
A method comprising: receiving, at a mobile device (602, 720), a handover command for moving from a source enhanced node B to a target enhanced node B; and sending a Packet Data Convergence Protocol, PDCP, status report through a PDCP layer to the source enhanced node B from the mobile device after the handover command and prior to the mobile device re-pointed to the target enhanced node B, wherein the PDCP status report comprises at least one PDCP sequence number that is appended to an Radio Link Control, RLC, Service Data Unit, SDU, by the PDCP layer, the at least one PDCP sequence number being constant across enhanced node Bs in the wireless communication system and independent from RLC Protocol Data Unit, PDU, sequence numbering, wherein RLC PDU information for the source enhanced node B link is not relevant to the target enhanced node B link. receiving, at a mobile device (602, 720), a handover command for moving from a source enhanced node B to a target enhanced node B; and sending a Packet Data Convergence Protocol, PDCP, status report through a PDCP layer to the source enhanced node B from the mobile device after the handover command and prior to the mobile device re-pointed to the target enhanced node B, wherein the PDCP status report comprises at least one PDCP sequence number that is appended to an Radio Link Control, RLC, Service Data Unit, SDU, by the PDCP layer, the at least one PDCP sequence number being constant across enhanced node Bs in the wireless communication system and independent from RLC Protocol Data Unit, PDU, sequence numbering, wherein RLC PDU information for the source enhanced node B link is not relevant to the target enhanced node B link.
Process for obtaining trimethylolpropane-enriched product streams from the forerun fractions obtained in the distillative purification of trimethylolpropane, characterized in that: (a) the forerun fractions are treated separately or in combination at a temperature of 160 to 280°C and at a pressure of 1 to 30 MPa with hydrogen in the presence of a hydrogenation catalyst and an acidic compound; and (b) the reaction mixture obtained after step a) is separated by distillation into a trimethylolpropane-enriched, catalyst-free product stream and a catalyst-containing product stream, wherein trimethylolpropane is prepared by the Cannizzaro process using alkali metal or alkaline earth metal compounds or stoichiometric amounts of trialkylamines, or is produced by the hydrogenation process in the presence of catalytic amounts of trialkylamines or alkali metal or alkaline earth metal compounds. (a) the forerun fractions are treated separately or in combination at a temperature of 160 to 280°C and at a pressure of 1 to 30 MPa with hydrogen in the presence of a hydrogenation catalyst and an acidic compound; and (b) the reaction mixture obtained after step a) is separated by distillation into a trimethylolpropane-enriched, catalyst-free product stream and a catalyst-containing product stream, wherein trimethylolpropane is prepared by the Cannizzaro process using alkali metal or alkaline earth metal compounds or stoichiometric amounts of trialkylamines, or is produced by the hydrogenation process in the presence of catalytic amounts of trialkylamines or alkali metal or alkaline earth metal compounds.
A living body tissue three-dimensional model, wherein said living body tissue three-dimensional model reconstructs a thickness of a lumen wall portion of a blood vessel including a lesion region of a living body tissue, wherein said living body tissue three-dimensional model is produced by a step of lamination shaping using tomographic data of the lesion region, the tomographic data being based on three-dimensional data of the lesion region of the living body tissue, wherein the thickness of the lumen wall portion of the blood vessel including the lesion region is reconstructed by extracting a boundary between the lumen wall portion of the blood vessel and other tissues of the lesion region based on anatomical information of dissections of patients having the same affection, characterized in that the living body tissue three-dimensional model produced based on the lesion region tomographic data has flow indicating elements which are small pieces each in the form of a thin plate formed in a projecting manner from the lumen wall portion toward the lumen, the flow indicating elements each having a flexible thin leg portion and a flow abutting portion of a greater width than that of the leg portion, the flow abutting portion being formed at an end portion of the leg portion, wherein, when fluid flows in the lumen surrounded by the lumen wall portion and is brought into abutment with the flow abutting portion, the flow abutting portion is inclined or is turned so as to change the direction by force from the fluid. said living body tissue three-dimensional model reconstructs a thickness of a lumen wall portion of a blood vessel including a lesion region of a living body tissue, wherein said living body tissue three-dimensional model is produced by a step of lamination shaping using tomographic data of the lesion region, the tomographic data being based on three-dimensional data of the lesion region of the living body tissue, wherein the thickness of the lumen wall portion of the blood vessel including the lesion region is reconstructed by extracting a boundary between the lumen wall portion of the blood vessel and other tissues of the lesion region based on anatomical information of dissections of patients having the same affection, characterized in that the living body tissue three-dimensional model produced based on the lesion region tomographic data has flow indicating elements which are small pieces each in the form of a thin plate formed in a projecting manner from the lumen wall portion toward the lumen, the flow indicating elements each having a flexible thin leg portion and a flow abutting portion of a greater width than that of the leg portion, the flow abutting portion being formed at an end portion of the leg portion, wherein, when fluid flows in the lumen surrounded by the lumen wall portion and is brought into abutment with the flow abutting portion, the flow abutting portion is inclined or is turned so as to change the direction by force from the fluid.
A disposable heat exchanger cartridge for thermally treating fluid for treatment of a patient with a cooling device that includes a thermal plate, the cartridge comprising: a first plate having a thermally conductive surface coupled to a second plate thereby defining a fluid channel that extends through the cartridge with at least a portion of the fluid channel arranged adjacent to the thermally conductive surface; the cartridge being removably couplable via a biasing mechanism to the thermal plate of the cooling device such that the thermally conductive surface conductively cools the fluid, characterized in that the cartridge includes an inlet port formed at a first end of the fluid channel in fluid communication with the inlet supply line and an outlet port at a second end of the fluid channel, in fluid communication with the outlet supply line, the inlet port and outlet port having a sloped profile with a starting depth greater than a depth of the fluid channel and sloping downward to a depth of the fluid channel.
Adapter unit which is provided for coupling, in particular releasable coupling, of a wiper blade to a wiper arm, having a wind deflector surface which is designed to deflect inflowing air and press the wiper blade onto a vehicle glass, wherein the wind deflector surface has at least one first sub-face and a second sub-face, wherein the first sub-face has a different orientation than the second sub-face and/or wherein the first sub-face has a different geometry than the second sub-face, and the first sub-face and/or the second sub-face are/is designed to be flat or largely flat at least in regions, characterized by a face which faces the wiper arm and is designed to guide through and/or receive the wiper arm for coupling to the adapter unit, wherein the face facing the wiper arm is tilted relative to a surface normal of an adapter unit base area by a right-hand angle between 10° and 40°, preferably between 20° and 30°, characterized in that a dividing line between the first sub-face and the second sub-face is oriented at least in regions to be perpendicular and/or largely perpendicular to the wiper arm direction.
Lubrication device for a rapier comprising a chamber (20, 30) arranged and configured to receive a lubrication element for the rapier and a detection device (21, 33) for detecting a consumption of the lubrication element received in the chamber (20, 30), wherein the detection device (21, 33) is arranged and configured to detect an alert state prior to the lubrication element being entirely consumed, characterized in that the detection device (21, 33) is arranged and configured to detect at least after reaching the alert state a continued consumption and to output an alert signal, which alert signal varies with the continued consumption.
A dynamic method for detecting actual odorous molecules of interest contained in the atmosphere or in direct proximity to the atmosphere present in an enclosure comprising the following steps: a) Absorbing a sample of the atmosphere present in or proximate to said enclosure by means of an extraction device; b) Making said sample circulate/pass through and/or over a collection device capable of absorbing the actual odorous molecules of interest, said device being in the form of a hollow tube open at each of its ends; and c) Having said device analyzed by a detection animal and/or an analysis machine. a) Absorbing a sample of the atmosphere present in or proximate to said enclosure by means of an extraction device; b) Making said sample circulate/pass through and/or over a collection device capable of absorbing the actual odorous molecules of interest, said device being in the form of a hollow tube open at each of its ends; and c) Having said device analyzed by a detection animal and/or an analysis machine.
A system for delivering laser treatment into a cornea of an eye, the system comprising: a laser capable of generating a pulsed laser beam and a delivery system configured to deliver the pulsed laser beam to a target in the cornea of the eye; an XY-scan device to move the scan line; a Z-scan device to modify a Z location of a focus of the pulsed laser beam in a z direction along an optical axis; and a controller configured to control the XY-scan device and the Z-scan device to focus the pulsed laser beam into a pattern of spaced focal spots that form a top lenticular incision and a bottom lenticular incision of a lens in the eye; wherein the focal spots have a diameter between 0.9 μm and 1.11 μm; characterized in that the spaced focal spots in the pattern overlap. a laser capable of generating a pulsed laser beam and a delivery system configured to deliver the pulsed laser beam to a target in the cornea of the eye; an XY-scan device to move the scan line; a Z-scan device to modify a Z location of a focus of the pulsed laser beam in a z direction along an optical axis; and a controller configured to control the XY-scan device and the Z-scan device to focus the pulsed laser beam into a pattern of spaced focal spots that form a top lenticular incision and a bottom lenticular incision of a lens in the eye; wherein the focal spots have a diameter between 0.9 μm and 1.11 μm; characterized in that the spaced focal spots in the pattern overlap.
A method of monitoring cardiorenal syndrome in a patient, comprising: a. performing an assay method that detects NGAL on a body fluid sample obtained from said patient, thereby providing an NGAL assay result; b. performing an assay method that detects one or more of BNP, NT-proBNP and proBNP on the same or a different body fluid sample obtained from said patient, thereby providing a natriuretic peptide assay result; and c. relating the NGAL assay result and the natriuretic peptide assay result to the patient's cardiorenal syndrome status by comparing said NGAL assay result to a baseline NGAL result and comparing said natriuretic peptide assay result to a baseline natriuretic peptide result, and assigning a worsening cardiorenal syndrome status to said patient when both said NGAL assay result is greater than said baseline NGAL result and said natriuretic peptide assay result is greater than said baseline natriuretic peptide result, relative to a status assigned when said NGAL assay result is less than said baseline NGAL result and said natriuretic peptide assay result is less than said baseline natriuretic peptide result, or by assigning an improving cardiorenal syndrome status to said patient when both said NGAL assay result is less than said baseline NGAL result and said natriuretic peptide assay result is less than said baseline natriuretic peptide result, relative to a status assigned when said NGAL assay result is greater than said baseline NGAL result and said natriuretic peptide assay result is greater than said baseline natriuretic peptide result. a. performing an assay method that detects NGAL on a body fluid sample obtained from said patient, thereby providing an NGAL assay result; b. performing an assay method that detects one or more of BNP, NT-proBNP and proBNP on the same or a different body fluid sample obtained from said patient, thereby providing a natriuretic peptide assay result; and c. relating the NGAL assay result and the natriuretic peptide assay result to the patient's cardiorenal syndrome status by comparing said NGAL assay result to a baseline NGAL result and comparing said natriuretic peptide assay result to a baseline natriuretic peptide result, and assigning a worsening cardiorenal syndrome status to said patient when both said NGAL assay result is greater than said baseline NGAL result and said natriuretic peptide assay result is greater than said baseline natriuretic peptide result, relative to a status assigned when said NGAL assay result is less than said baseline NGAL result and said natriuretic peptide assay result is less than said baseline natriuretic peptide result, or by assigning an improving cardiorenal syndrome status to said patient when both said NGAL assay result is less than said baseline NGAL result and said natriuretic peptide assay result is less than said baseline natriuretic peptide result, relative to a status assigned when said NGAL assay result is greater than said baseline NGAL result and said natriuretic peptide assay result is greater than said baseline natriuretic peptide result.